XERS: Xeris Biopharma Holdings Inc insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 4 sales totaling $595K in the last 180 days.
Insider sales
| Trade date | Insider | Role | Value | 10b5-1 plan |
|---|---|---|---|---|
| 2026-10-01 | Pieper Steven | Officer | $47K | yes |
| 2026-10-01 | Mcculloch Kevin | Officer | $141K | yes |
| 2026-10-01 | Hecht Beth | Officer | $157K | yes |
| 2026-09-28 | Mcculloch Kevin | Officer | $250K | yes |
Activist and 5% holders
| Filed | What | Holder | Stake | Change | Filing |
|---|---|---|---|---|---|
| 2026-07-31 | New 13G stake | Vanguard Capital Management | 5.00% | SEC |
Institutional ownership (Q2 2026)
240 institutions reported holding $849.77M of Xeris Biopharma Holdings Inc on Form 13F (237 the quarter before). 32 opened a new position and 28 sold out. Shares held by institutions: +3%.
| Largest holders | Shares | Value |
|---|---|---|
| BlackRock, Inc. | 14,525,539 | $115.04M |
| D. E. Shaw & Co., Inc. | 7,804,758 | $61.81M |
| VANGUARD CAPITAL MANAGEMENT LLC | 7,340,229 | $58.13M |
| STATE STREET CORP | 4,821,566 | $38.19M |
| GEODE CAPITAL MANAGEMENT, LLC | 4,718,183 | $37.37M |
| Nuveen, LLC | 4,385,141 | $34.73M |
| Rosalind Advisors, Inc. | 2,908,981 | $23.04M |
| Qube Research & Technologies Ltd | 2,893,749 | $22.92M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 2,626,208 | $20.80M |
| WELLINGTON MANAGEMENT GROUP LLP | 2,365,103 | $18.73M |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.